ID   KTC1res.2
AC   CVCL_A2CT
SY   KTC1res_2; Res.2 KTC1
DR   cancercelllines; CVCL_A2CT
DR   Cosmic; 2755724
DR   Wikidata; Q105509842
RX   PubMed=29156680;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; PLX4032).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=29156680).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=29156680).
CC   Sequence variation: Mutation; HGNC; 9801; RAC1; Simple; p.Asp63Val (c.188A>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Heterozygous; Note=In promoter (from parent cell line).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C6040; Poorly differentiated thyroid gland carcinoma
DI   ORDO; Orphanet_100088; Thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_6300 ! KTC-1
SX   Male
AG   68Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 05-10-23; Version: 6
//
RX   PubMed=29156680; DOI=10.18632/oncotarget.21262; PMCID=PMC5689570;
RA   Antonello Z.A., Hsu N., Bhasin M., Roti G., Joshi M., Van Hummelen P.,
RA   Ye E., Lo A.S., Karumanchi S.A., Bryke C.R., Nucera C.;
RT   "Vemurafenib-resistance via de novo RBM genes mutations and chromosome
RT   5 aberrations is overcome by combined therapy with palbociclib in
RT   thyroid carcinoma with BRAF(V600E).";
RL   Oncotarget 8:84743-84760(2017).
//